PeppiLibrary

Metabolic

Liraglutide peptide reference

First-generation long-acting GLP-1 agonist. Daily injection.

Last reviewed May 6, 2026 FDA-approved FDA approved
Peppi reviewing Liraglutide notes
Default dose label600 mcg
Preferred routeSubQ
Frequency label1× daily
Storage window30 days mixed

Evidence snapshot

FDA-approved

Evidence maturityFDA approved
FDA-approved with extensive Phase 3 trials (LEAD, SCALE programs)

Prescription medication

Route map

How records are usually labeled

1 SubQ

Rotate daily between sites to minimise lipohypertrophy.

Vial timeline

Storage cues to log

Before mixRefrigerate 2–8 °C; do not freeze.
After mixPen in use: room temperature ≤30 °C up to 30 days OR refrigerated.
Use-by cue30 days after mixing
Mixed vial window30 days
Use this as a record-keeping cue, not a replacement for product labeling.

Peppi workflow

From vial to review

Vial 18 mg vial
Dose 600 mcg
Route SubQ
Review 30d storage

Peppi turns scattered dose, vial, route, storage, note, and report details into one record trail.

Educational reference only

This page helps you understand what to track for Liraglutide. It is not medical advice, a prescription, or a recommendation to use this peptide. Discuss dose, route, timing, storage, and safety with a qualified healthcare professional.

Overview

Liraglutide is a 31-amino-acid GLP-1 receptor agonist developed by Novo Nordisk. It carries a C16 fatty-acid chain that binds plasma albumin, extending its half-life enough for once-daily dosing — the first GLP-1 to make this leap. Approved as Victoza (T2D, 2010) and Saxenda (chronic weight management, 2014). Largely superseded by weekly semaglutide and tirzepatide for most indications.

Also known as: Victoza, Saxenda.

Type 2 diabetes glycemic control (Victoza)Chronic weight management (Saxenda)Cardiovascular risk reduction in T2D

Mechanism and timing snapshot

GLP-1 receptor agonist. Stimulates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite via central pathways.

Onset labelNot listed
Catalog onset field, when available.
Half-life label13 hr
~13 hours; daily dosing reaches steady state in ~3 days
Duration label24 hr
Catalog duration field, when available.
subQ ~55%
oral Negligible

Tracking defaults

These values come from Peppi's catalog so records can be prefilled consistently. They should be reviewed against your clinician's instructions before logging real-world use.

Catalog default dose600 mcg
Catalog dose range600 mcg - 3 mg
Default routeSubQ
Frequency label1× daily
Best time labelSame time each day, with or without food.
Food noteNone significant for the injectable form.

Catalog protocol note

Saxenda: 0.6 mg daily × 1 week → 1.2 mg × 1 week → 1.8 mg × 1 week → 2.4 mg × 1 week → 3.0 mg ongoing. Victoza max: 1.8 mg.

Routes and site notes

Available route labelsSubQ
Preferred route labelSubQ
Common site labelsAbdomen, Thigh, Upper arm
Site rotation noteRotate daily between sites to minimise lipohypertrophy.

Chemistry

SequenceModified GLP-1(7-37) with C16 fatty acid attached via γ-Glu spacer at K26
Amino acids31
Molecular formulaC172H265N43O51
Molecular weight3751.2 Da

Vial, reconstitution, and storage

Supply formPre-filled multi-dose pen
Typical vial size18 mg
DiluentN/A — pre-mixed solution
Diluent volumeNot listed
Concentration notePre-filled pen at 6 mg/mL; pen dial selects dose.
Before reconstitutionRefrigerate 2–8 °C; do not freeze.
After reconstitutionPen in use: room temperature ≤30 °C up to 30 days OR refrigerated.
Reconstituted shelf life30 days
Light sensitiveYes
Freeze/thaw warningYes

Safety notes

Common and rare side effects listed in the catalog

  • Nausea (~25%)
  • Diarrhea or constipation
  • Headache
  • Decreased appetite
  • Injection-site reactions
  • Pancreatitis
  • Gallbladder issues
  • Acute kidney injury from dehydration

Contraindications and warnings

  • Personal/family history of medullary thyroid carcinoma
  • MEN 2 syndrome
  • Pregnancy
  • FDA boxed warning for thyroid C-cell tumours (rodent data).
  • Discontinue if pancreatitis suspected.

Other considerations

  • Daily injection — less convenient than weekly semaglutide.
  • Generally cheaper than semaglutide on cash-pay; insurance coverage varies.
  • Slow titration is essential for tolerability.

Evidence and regulatory context

Evidence levelFDA-approved with extensive Phase 3 trials (LEAD, SCALE programs)
FDA approvedYes
Regulatory statusPrescription medication
Prescription requiredYes
Approved countriesUS, EU, UK, Canada, Japan, and many others

Stacking and cycle notes

Stacks well withNot listed
Avoid combining noteOther GLP-1 agonists, DPP-4 inhibitors
Typical cycle labelongoing
Typical break labelNot typically cycled
Cycle guidanceUsed continuously; weight regain often follows discontinuation.

Tracking tips

  • Set a daily alarm — daily cadence is easier to forget than weekly.
  • Consider semaglutide if you struggle with daily adherence.
  • Start at 0.6 mg and titrate slowly to manage GI side effects.

References

Track it in Peppi

Keep Liraglutide records organized.

Use Peppi for dose logs, vial inventory, storage dates, reminders, journal notes, photos, and clinician-ready reports.

Download on theApp Store Get it onGoogle Play

FAQ

What should I track for Liraglutide?

Track the peptide name, dose amount and unit, route, vial label, timing, reconstitution or expiration dates, storage notes, and any symptoms or questions for clinician review.

Does Peppi tell me how to use Liraglutide?

No. Peppi organizes educational reference and your own records. Protocol decisions should come from a qualified healthcare professional.

Can I export Liraglutide records?

Peppi is designed to keep dose logs, vial inventory, journal notes, and reports easier to review and export.

Last reviewed: May 6, 2026